trial

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCTId NCT01885338
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 26 (actual)
Sponsored by VA Greater Los Angeles Healthcare System
Primary completion 2014-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
26 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-06
Primary completion
2014-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
N-acetylcysteine (NAC)

Sponsors

VA Greater Los Angeles Healthcare SystemLead Sponsor
VISN 22 Mental Illness Research, Education, and Clinical CenterCollaborator
American Psychiatric FoundationCollaborator

Investigators

2
Stephen J Heishman, Ph.D.Principal Investigator
Michael C Davis, M.D., Ph.D.Principal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
26
Phase
PHASE1
Primary Completion Date
2014-05
Status
COMPLETED
relationships
The graph out of here
drug
N-acetylcysteine (NAC)
drug
lead_sponsor
VA Greater Los Angeles Healthcare System
company
collaborator
VISN 22 Mental Illness Research, Education, and Clinical Center
company
American Psychiatric Foundation
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stephen J Heishman, Ph.D.
person
Michael C Davis, M.D., Ph.D.
person